KNW Know Labs
- 0.650
- +0.010+1.55%
Know Labs News
Know Labs Initiated at Speculative Buy by Benchmark
Know Labs Initiated at Speculative Buy by Benchmark
Know Labs Price Target Announced at $1.00/Share by Benchmark
Know Labs Price Target Announced at $1.00/Share by Benchmark
Express News | Benchmark Initiates Coverage On Know Labs With Speculative Buy Rating, Announces Price Target of $1
Know Labs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/08/2024 56.01% Benchmark → $1 Initiates Coverage On → Speculative Buy
Know Labs to Present Clinical Research at the 2024 American Physiology Summit
The Company demonstrates significant progress since presenting at last year's Summit. Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been
Know Labs Reports Promising Results From Clinical Study
Know Labs' Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study
Know Labs' first study including participants with diabetes and venous blood as a comparative reference demonstrates its proprietary sensor's accuracy and medical application.SEATTLE--(BUSINESS WIRE)-
Dawson James Downgrades Know Labs Stock to Neutral, Withdraws 12-month PT
Know Labs to Raise up to $12M for Non-invasive CGM Tech
Know Labs Secures $12 Million Investment From Lind
Know Labs Secures U.S. $12 Million Funding for Company's Further Execution on Its Clinical Research and Development Initiatives
Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has entered into a funding agreement for an investment of up to $12 million, of which it has executed a
Know Labs Announces the KnowU, Its Wearable Non-Invasive Continuous Glucose Monitor
The KnowU incorporates the sensor intended for FDA submission Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the KnowU, its wearable
Earnings Call: Know Labs Reports Q1 Financials, Plans for Future Funding
Earnings Call Summary | Know Labs(KNW.US) Q1 2024 Earnings Conference
The following is a summary of the Know Labs, Inc. (KNW) Q1 2024 Earnings Call Transcript:Financial Performance:Know Labs reported a Q1 net loss of $3.45 million, down 9.8% from a net loss of $3.82 mil
Express News | Know Labs Q1 EPS $(0.04) Up From $(0.08) YoY
Know Labs GAAP EPS of -$0.04
Press Release: Know Labs, Inc. Reports First Quarter FY2024 Results
Know Labs, Inc. Reports First Quarter FY2024 Results SEATTLE--(BUSINESS WIRE)--February 14, 2024-- Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic tech
Earnings Scheduled For February 14, 2024
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earnings at $1.65 per share on revenue of $24.62 billion. • CAE (NYSE:CAE) is estimated to report quarterl
Press Release: Know Labs, Inc. to Host Review of First Quarter Fiscal Year 2024 Results on February 14, 2024
Know Labs, Inc. to Host Review of First Quarter Fiscal Year 2024 Results on February 14, 2024 SEATTLE--(BUSINESS WIRE)--February 07, 2024-- Know Labs, Inc. (NYSE American: KNW), an emerging develope
Know Labs to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
The Company to present updated clinical research results and developments of its non-invasive blood glucose monitor Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology,
Analysis
Price Target
No Data
